New drug cocktail aims to improve survival in advanced head and neck cancer
Disease control
Not yet recruiting
This study tests whether combining the immunotherapy drug camrelizumab with either an EGFR antibody or chemotherapy can help people with advanced head and neck cancer live longer. About 246 adults with stage III or IV head and neck squamous cell carcinoma will receive the treatme…
Phase: PHASE3 • Sponsor: Yue He, MD • Aim: Disease control
Last updated May 06, 2026 16:15 UTC